Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Barclays Maintains Overweight on Teladoc Health, Lowers Price Target to $20

Author: Benzinga Newsdesk | April 26, 2024 09:19am
Barclays analyst Steve Valiquette maintains Teladoc Health (NYSE:TDOC) with a Overweight and lowers the price target from $25 to $20.

Posted In: TDOC

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist